EyePoint周一表示，将裁员约53%，并停止其针对老年人视力相关疾病的实验性眼科药物的研究，因为该药物在第二次晚期试验中失败。
EyePoint on Monday said it would cut about 53% of its workforce and stop studies of its experimental eye drug for an age-related vision disease after it failed a second late-stage trial.
该试验将EyePoint的Duravyu与强生的（REGN.O）畅销眼科药物Eylea进行比较，对象是患有湿性年龄相关性黄斑变性的患者，这是老年人失明的主要原因。虽然接受Duravyu治疗的患者视力有所改善，但该药物未能证明其在保护视力方面与标准治疗同样有效，EyePoint表示。截至2月27日，根据监管文件，EyePoint在美国全职员工共计214人。
Here are more details:
此次挫折继8月份类似失败之后发生，当时Duravyu在一项相同的晚期研究中未达到主要目标，导致其股价暴跌超过65%。EyePoint表示，裁员和终止试验预计每年可节省约3000万美元。公司估计将记录约900万美元的相关遣散费用。EyePoint表示，将把焦点和资源转向开发Duravyu用于治疗糖尿病性黄斑水肿，这是另一种视网膜疾病，晚期试验结果预计将在2027年第四季度出炉。
The trial tested EyePoint's Duravyu against Regeneron's (REGN.O) blockbuster eye medicine Eylea in patients with wet age-related macular degeneration, a leading cause of blindness in older adults While patients given Duravyu showed improved vision, the drug failed to prove as effective as the standard treatment in preserving eyesight, EyePoint said The company had 214 full-time employees as of February 27, all based in the US, according to a regulatory filing The setback follows a similar failure in August, when Duravyu missed the main goal in an identical late-stage study, triggering a more than 65% fall in its shares EyePoint said the workforce reduction and ending of trials was expected to save about $30 million annually The company estimates it will record roughly $9 million in related severance charges EyePoint said it will shift its focus and resources to developing Duravyu for diabetic macular edema, another retinal disease, with late-stage trial results expected in the fourth quarter of 2027